A next-generation pneumococcal conjugate vaccine, PCV20, a single-dose protection is now available in India marking a new ...

Pfizer has launched its 20-valent pneumococcal conjugate vaccine (PCV20) in India, offering single-dose protection against 20 ...

For decades, doctors have worked to protect people from Streptococcus pneumoniae, a bacterium responsible for pneumonia, ...

Pfizer’s PCV20 offers single-shot protection against 20 pneumococcal serotypes, safeguarding adults from serious respiratory ...

In a recent multicenter prospective study conducted at three hospitals in Tennessee and Georgia, including Vanderbilt ...

Single-dose PCV20 approved for adults 18 years and older, covering 20 pneumococcal serotypes, including both invasive and non ...

Pfizer Inc (($PFE)) announced an update on their ongoing clinical study. Pfizer Inc. is conducting a Phase 1 clinical study titled ‘A Phase 1, ...

Among patients hospitalized with community-acquired pneumonia in Georgia and Tennessee, 14% had pneumococcal pneumonia.

In a recent multicenter prospective study conducted at three hospitals in Tennessee and Georgia, including Vanderbilt University Medical Center ...

The "Pneumococcal Disease - Pipeline Insight, 2025" report offers in-depth analysis of over 20 drugs and 18 companies in the Pneumococcal Disease pipeline, covering clinical and nonclinical stages.

Since the implementation of Streptococcus pneumoniae (SPn) conjugate vaccination (PCV), non-vaccine types have prevailed in invasive pneumococcal disease (IPD), and an increase in Staphylococcus ...